REG - Convatec Group PLC - Update regarding Chief Executive Officer

ConvaTecAnnouncement

04/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250804:nRSD7990Ta&default-theme=true

RNS Number : 7990T  Convatec Group PLC  04 August 2025

Contains Inside Information

 

Convatec Group Plc ("Convatec" or "the Company")

 

Update regarding Chief Executive Officer

 

London, UK, 04 August 2025: Convatec Chief Executive Officer Karim Bitar will
be taking a medical leave of absence from the Company.

 

During this period of absence, Jonny Mason, currently Chief Financial Officer,
will become Interim Chief Executive Officer, and Fiona Ryder, currently Group
Financial Controller, will become Interim Chief Financial Officer. Jonny and
Fiona joined the Company in January 2022.

 

END

 

Contacts

The person responsible for making this announcement is James Kerton, Company
Secretary, Convatec Group plc: cosec@convatec.com

 

Media: MediaRelations@convatec.com

 

Investor Relations: IR@convatec.com

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than
10,000 colleagues, we provide products and services in around 90 countries,
united by a promise to be forever caring. Our solutions provide a range of
benefits, from infection prevention and protection of at-risk skin to improved
patient outcomes and reduced care costs. Convatec's revenues in 2024 were over
$2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To
learn more please visit http://www.convatecgroup.com
(https://www.convatecgroup.com/)

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUPWRUPAGRW